503 related articles for article (PubMed ID: 17967833)
21. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
[TBL] [Abstract][Full Text] [Related]
22. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
[TBL] [Abstract][Full Text] [Related]
23. Etanercept: new indication. For ankylosing spondylitis: another option.
Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
[TBL] [Abstract][Full Text] [Related]
24. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
de Vries MK; van der Horst-Bruinsma IE; Nurmohamed MT; Aarden LA; Stapel SO; Peters MJ; van Denderen JC; Dijkmans BA; Wolbink GJ
Ann Rheum Dis; 2009 Apr; 68(4):531-5. PubMed ID: 18375542
[TBL] [Abstract][Full Text] [Related]
26. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
Inman RD; Maksymowych WP;
J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.
Braun J; van der Horst-Bruinsma IE; Huang F; Burgos-Vargas R; Vlahos B; Koenig AS; Freundlich B
Arthritis Rheum; 2011 Jun; 63(6):1543-51. PubMed ID: 21630245
[TBL] [Abstract][Full Text] [Related]
28. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
Woo JH; Lee HJ; Sung IH; Kim TH
J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
[TBL] [Abstract][Full Text] [Related]
29. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial.
Dougados M; Combe B; Braun J; Landewé R; Sibilia J; Cantagrel A; Feydy A; van der Heijde D; Leblanc V; Logeart I
Ann Rheum Dis; 2010 Aug; 69(8):1430-5. PubMed ID: 20511606
[TBL] [Abstract][Full Text] [Related]
30. [A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis].
Huang F; Zhang J; Huang JL; Wu DH; Li ZG; Chen SL; Pan YF; Ma L; Chen S; Lü LJ; Yang ZM
Zhonghua Nei Ke Za Zhi; 2010 Sep; 49(9):741-5. PubMed ID: 21092442
[TBL] [Abstract][Full Text] [Related]
31. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C
Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842
[No Abstract] [Full Text] [Related]
32. Etanercept treatment for children and adolescents with plaque psoriasis.
Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE
Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
[TBL] [Abstract][Full Text] [Related]
34. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.
van der Heijde D; Braun J; Dougados M; Sieper J; Pedersen R; Szumski A; Koenig AS
Rheumatology (Oxford); 2012 Oct; 51(10):1894-905. PubMed ID: 22772319
[TBL] [Abstract][Full Text] [Related]
35. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
Moore A; Gordon KB; Kang S; Gottlieb A; Freundlich B; Xia HA; Stevens SR
J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
Horneff G; Ebert A; Fitter S; Minden K; Foeldvari I; Kümmerle-Deschner J; Thon A; Girschick HJ; Weller F; Huppertz HI
Rheumatology (Oxford); 2009 Aug; 48(8):916-9. PubMed ID: 19483091
[TBL] [Abstract][Full Text] [Related]
37. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
Mease PJ; Woolley JM; Singh A; Tsuji W; Dunn M; Chiou CF
J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept.
Baraliakos X; Davis J; Tsuji W; Braun J
Arthritis Rheum; 2005 Apr; 52(4):1216-23. PubMed ID: 15818694
[TBL] [Abstract][Full Text] [Related]
39. Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis.
Wanders AJ; Gorman JD; Davis JC; Landewe RB; van der Heijde DM
Arthritis Rheum; 2004 Feb; 51(1):1-8. PubMed ID: 14872448
[TBL] [Abstract][Full Text] [Related]
40. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis.
van Denderen JC; van der Paardt M; Nurmohamed MT; de Ryck YM; Dijkmans BA; van der Horst-Bruinsma IE
Ann Rheum Dis; 2005 Dec; 64(12):1761-4. PubMed ID: 15901634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
